PharmaEssentia vs TTY Biopharm
PharmaEssentia
Taiwanese biopharma selling BESREMi, an interferon injection for a rare blood cancer
TTY Biopharm
Taiwan specialty pharma making oncology drugs like Lipo-Dox and generics
Dimension by dimension
| Dimension | PharmaEssentia | TTY Biopharm |
|---|---|---|
| Exposure to AI | PharmaEssentia's interferon injection BESREMi is also unlikely to be absorbed by AI. | TTY's liposomal cancer drugs and licensed therapies are unlikely to be absorbed by AI. |
| How easily a giant copies them | PharmaEssentia's approach is also blocked from easy copying by a large competitor. | TTY's approach is blocked from easy copying by a large competitor. |
| Pressure from rivals | PharmaEssentia faces a named threat from Takeda and Protagonist's rusfertide, which could take first-line share after an FDA decision expected in Q3 2026. | TTY faces Lotus Pharmaceutical, a same-industry Taiwanese peer expanding regionally, but no confirmed customer losses are recorded. |
| Revenue growth | PharmaEssentia's global revenue rose 66% year over year to $504 million, with its TWSE filing showing 60.6% growth to NT$15.63 billion. | TTY's revenue was roughly flat, moving from NT$6.45 billion in FY2025 to NT$6.51 billion on a trailing basis. |
| Financial footing | PharmaEssentia's disclosed numbers cover revenue growth only, with no net income figure given. | TTY reported FY2025 net income of NT$1.56 billion alongside its revenue figures. |
| Strength of protection around the business | PharmaEssentia's competitive protection is assessed as stronger than TTY's, based on its blocked-to-copy production approach and the named rival threat from Takeda's rusfertide, assessed July 2026. | TTY's competitive protection is assessed as moderate, based on its blocked-to-copy production approach, assessed July 2026. |
Questions people ask
- Is PharmaEssentia growing faster than TTY Biopharm
- Yes, PharmaEssentia's revenue grew 66% year over year to $504 million globally and 60.6% on its Taiwan exchange filing. TTY Biopharm's revenue stayed close to flat, moving from NT$6.45 billion to NT$6.51 billion on a trailing basis.
- Are TTY Biopharm and PharmaEssentia at risk from AI replacing their products
- Neither company faces meaningful AI exposure. TTY Biopharm's cancer drugs and PharmaEssentia's interferon injection BESREMi are both rated unlikely to be absorbed by AI.
- What is the biggest risk facing PharmaEssentia
- The biggest named risk is rusfertide, a drug from Takeda and Protagonist that could take first-line share in PharmaEssentia's core disease area after an FDA decision expected in Q3 2026. TTY Biopharm's main named risk is Lotus Pharmaceutical's regional expansion, though no customer losses have been confirmed there.
- Does TTY Biopharm or PharmaEssentia have better financial numbers
- TTY Biopharm reports a net income figure of NT$1.56 billion for FY2025 alongside its revenue. PharmaEssentia's disclosed figures show strong revenue growth of 66% year over year but do not include a net income number in the data given.